Genmab — November 2014
-
Han har vist tidligere nævnt at det Warhead (ADC teknologi) fra ADC Therapeutics potentielt er 100 gange mere potent end den fra SGEN
-
Ibrutinib har allerede en runway som blockbuster. 280 mio. $ i salg i sidste kvartal. Det er bedre lunch end Gazyvaro
-
Og de skraber kun overfladen af hva det kan. Intet frontline, DLBCL, FL osv. endnu. Kun MCL og R/R CLL
-
deres 3 første approvals. 2 i USA og 1 i EU har givet over 250 mio. $ i regulatoriske milepæle..
-
Glæder mig til Daratumumab skal igennem denne proces
-
To date, in addition to the upfront payment of $150 million from Janssen, the Company has earned milestone payments of $585 million under the Agreement and maintains the potential to receive up to an additional $240 million ($50 million for development progress, $70 million for regulatory progress and $120 million for approval) in development, regulatory and approval milestone payments, assuming specific targets are achieved.
-
phase II som vil evaluere dara i 3 forskellige behandlingsregimenter.. Syntes det er fint de starter med et phase II i smoldering
-
og ikke bare kører et phase III. Det er vigtigt at lave forarbedjet ordentligt i denne indikation da den er lidt anderledes end normal MM. Men det potentielle markedspotentiale er enormt.
-
282 brudt nu
-
284
-
flot luk omkring 285
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind